

Azure Health Technology Limited appoints Non-Executive Director

Sydney, Australia 2 July 2020 – Azure Health Technology Limited (AZT) is pleased to announce the appointment of Andrew Bristow as a non-executive director.

Andrew is a highly experienced solicitor. He specialises in corporate and commercial law with a focus on initial public offerings and capital raising for both listed and unlisted companies. Andrew has listed over 20 companies in a wide range of industries including mining, stockbroking, toll-roads, education, manufacturing and software. Andrew also acts as Company Secretary for several listed and unlisted companies and is the representative of a nominated adviser on the NSX.

For more information please contact:

Ms Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200

About Azure Health Technology Limited

Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: www.azureht.com.au